Impact of upfront adjuvant chemoradiation on survival in patients with molecularly defined oligodendroglioma: the benefits of PCV over TMZ.
Rincon-Torroella J, Rakovec M, Kalluri AL, Jiang K, Weber-Levine C, Parker M, Raj D, Materi J, Sepehri S, Ferres A, Schreck KC, Aldecoa I, Lucas CG, Sair HI, Redmond KJ, Holdhoff M, Weingart J, Brem H, Sánchez JJG, Ye X, Bettegowda C.
Rincon-Torroella J, et al. Among authors: sanchez jjg.
J Neurooncol. 2024 Oct 9. doi: 10.1007/s11060-024-04829-6. Online ahead of print.
J Neurooncol. 2024.
PMID: 39382617